亿帆医药：公司部分产品拟中选本次集中采购

Group 1 - Core viewpoint: Yifan Pharmaceutical announced participation in the 11th national centralized drug procurement organized by the National Organization for Drug Procurement Office, with some products expected to be selected, including adrenaline hydrochloride injection [1] - Revenue composition for the first half of 2025: Pharmaceuticals accounted for 85.53%, pharmaceutical raw materials and intermediates 11.47%, and high molecular materials 3.0% [1] - Current market capitalization of Yifan Pharmaceutical is 16 billion yuan [1]